u/tired_ledger_notes

On the thin testing history in this board, and what to do about it.

Most of the compounds discussed here have a handful of independent results across the entire site, and several have none. That is a fact about how few members have paid for testing, not a judgement about the material.

What follows: buy small, test identity first for anything unusual, and post the result even when it is unremarkable. The vendor source pages are built from exactly these submissions, and the compounds with the thinnest coverage are the ones where one more entry changes the picture most. Research material is not approved for human use, so what this board can usefully build is an analytical record.

Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.

wait for phase 3 before you argue about rankings

What lead time were you quoted for that line?

What do you want from posting it — advice, or just to have it on the record?

Not convinced. A payment window that closed is a payment window, not evidence of intent.

if the price is impossible, the material is the thing being economised on

Yes — describe the sequence of events with dates. That is a report. Adjectives are not.

Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.

Panicked over a first-day sensor reading and rebuilt my week around it. It was the sensor.

Certain conditions affect A1c independently of glycaemia. If a result looks inconsistent with the sensor data, that is a question for whoever manages your care rather than for this board.

Are you being harder on yourself than you would be on somebody else posting this?

How long between the two A1c measurements?

research-use-only material is not approved for human use, full stop

Research-use-only material is not approved for human use. In this catalogue that covers essentially everything, which is why the board discusses material and analytics rather than outcomes.

Kept a log specifically because there is so little published. It is one person and it is not data.

Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.

wait for phase 3 before you argue about rankings

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

comparing reta phase 2 to sema phase 3 is comparing different things

sensor accuracy varies and the first day of a sensor is the worst

The group-buy structure, described neutrally, because the arguments here always get personal.

One person collects money, places one order, receives it, splits it and forwards it. That structure concentrates payment, custody and communication in a single point with no contract, no escrow and no recourse designed in. It is not an allegation about any organiser to say so.

What follows from it: the failure mode is silence rather than dispute, the people exposed have no visibility, and there is nothing to escalate to. If you take part, take part knowing the shape of what you have agreed to.

That is a report count, not a test count, and it changes how thin the evidence base actually is.

Is there any independent testing on file for this name anywhere?

That is body weight change, not fat mass. The trials report the first and people quote it as the second.

the escalation is where most of the reported trouble sits

Kept fingersticks alongside the sensor for two weeks to sanity-check it. Worth doing once.

This. Hypoglycaemia risk in this class is driven mostly by the other agents in the regimen.

Correction: that domain is one character different from the one you posted, which is rather the point of this thread.

Agreed — somebody is at exactly the point you were at, reading this, and it will land differently for them than any success story.

buy small first is the lesson that keeps being learned expensively

Disagreeing with the self-blame in this line. Some of it is luck and treating everything as a lesson is its own trap.

the TRIUMPH programme is still running, so anything definitive is premature

this board exists so the failures are on the record too

Agreed. The failures are the part that is missing from every other board, which is why this one matters.

the phase 2 numbers were striking and they were also 48 weeks in a small population

small trial, big effect, wide error bars

Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.

Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.

For any compound with a thin testing history, identity is the first question. Mass spectrometry against a theoretical mass answers it; an area-percent purity figure does not.

a lot of the confident posting here is extrapolation

This is the sentence the rest of the board should read first. Phase 2 is not a label.